Delivery Order SPE2DR25D3012-SPE2DR26F4E3T
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 20, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml quantities, valued at $1,526.88. This non-set-aside, firm fixed-price delivery order is scheduled for completion by November 21, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $2,471.23 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension in 120 ml quantities. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of November 25, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a $1,088.40 firm fixed price delivery order to AmerisourceBergen Drug Corp on December 10, 2025, for the supply of Quillivant XR 25 mg/5 mL suspension (180 mL). This non-set-aside contract represents a child delivery order executed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a...
- The Defense Logistics Agency awarded a $1,218.48 firm fixed-price delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 180 ml quantities, with performance completion scheduled for November 4, 2025. This non-set-aside award was competitively procured and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 17, 2025, for the supply of Quillivant XR 25 mg/5 mL suspension in 150 mL quantities, with a contract ceiling value of $2,802.86. This is a firm fixed-price delivery order with an ultimate completion date of November 18, 2025, with no set-aside designation applied. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania—the location of performance for this contract—is a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $1,918.07 to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 150 ml quantity. This non-competitive delivery order utilizes firm fixed pricing and maintains an ultimate completion date of August 26, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child delivery order, this award falls under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,980.57 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 mL suspension (180 mL) with an ultimate completion date of December 18, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded through competitive procedures. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml oral suspension (180ml) on December 2, 2025, with a ceiling value of $1,208.98. This firm fixed-price delivery order is scheduled for completion by December 3, 2025, and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award is non-set-aside and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a $1,918.40 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml quantities. This is a non-set-aside contract with performance scheduled for completion by August 5, 2025, with the place of performance located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order represents a child contract executed under...
- The Defense Logistics Agency awarded a $1,030.10 delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (180 ml), with an ultimate completion date of December 11, 2025. This is a firm fixed-price, non-set-aside contract utilizing a competitive award process. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal healthcare vendor that supplies a comprehensive portfolio of medications and medical...
- SPE2DR25D3012Indefinite Delivery Contract
- SPE2DR25D3012-SPE2DR26F4E3TDelivery Order
The Defense Logistics Agency awarded a $1,654.12 delivery order to AmerisourceBergen Drug Corp on January 5, 2026, for the supply of Quillivant XR 25 mg/5 ml suspension (120 ml). This firm fixed-price delivery order, with completion targeted for January 6, 2026, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The contract was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to meet federal pharmaceutical procurement requirements. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a primary pharmaceutical distributor supporting federal medical procurement for military and veteran healthcare systems. The company maintains an extensive portfolio of pharmaceutical deliveries under the DLA Medical Supply Chain, encompassing specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains. This delivery order for Quillivant XR—an extended-release formulation of methylphenidate used to treat attention deficit hyperactivity disorder—exemplifies the company's role in supplying critical pharmaceutical products to support Defense Health Agency and broader federal healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 1/4/26 |